For example, CRBN is highly expressed in the prostate tumor at both transcriptomic and proteomic levels, which aligned with the usage of CRBN hijacked by a PROTAC targeting androgen receptor (AR) in clinical trials in prostate cancer (NCT03888612; NCT04428788)1. Here, AR is linked to prostate neoplasm.